Description: <p><b>Arctigenin</b> — Arctigenin (ATG) is a dibenzylbutyrolactone lignan (the aglycone of arctiin) found notably in <i>Arctium lappa</i> (greater burdock) and related Asteraceae plants. It is a small-molecule natural product investigated for pleiotropic anti-inflammatory and anticancer activities in vitro and in vivo, with reported pathway effects spanning energy-stress signaling, PI3K/AKT–mTOR, and pro-survival transcriptional programs (e.g., STAT3, NF-κB). Common abbreviation: ATG.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Energy stress / immunometabolic suppression via AMPK-linked programs, with context-dependent inhibition of glycolysis/ATP generation and preferential cytotoxicity under nutrient stress</li>
<li>PI3K/AKT–mTOR axis suppression, including mTOR pathway inhibition with autophagy-associated cell death in some tumor models</li>
<li>STAT3 pathway inhibition (anti-proliferative / pro-apoptotic signaling shift in multiple cancer models)</li>
<li>NF-κB inflammatory signaling suppression (often downstream of PI3K/AKT/IKK inputs), reducing cytokine/pro-survival transcription in inflammatory disease and some tumor contexts</li>
<li>Cell-death reprogramming (apoptosis/autophagy balance; Bax/Bcl-2-family shifts reported in multiple models)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral exposure is constrained by metabolism: arctiin can be hydrolyzed by gut microbiota to arctigenin; arctigenin is then rapidly conjugated (notably glucuronidation; also sulfation), which can limit free-parent systemic exposure. Human PK exists for a burdock-fruit extract rich in arctigenin (GBS-01), showing measurable exposure with rapid conjugation.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic studies use micromolar concentrations; translation depends on whether free (unconjugated) arctigenin reaches comparable levels in target tissues. Conjugation-dominant PK implies that in-vitro potency may overestimate systemic free-drug activity unless delivery/exposure is enhanced or local (GI) effects dominate.</p>
<p><b>Clinical evidence status:</b> Early human evidence exists (small Phase I oncology study of GBS-01 in advanced pancreatic cancer; supportive PK/safety) plus limited human uptake/safety studies; anticancer efficacy remains unproven in RCTs.</p>
<h3>Arctigenin — cancer-relevant mechanistic axes (ranked)</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Energy stress signaling and metabolic vulnerability</td>
<td>↑ metabolic stress; ↓ ATP generation (context-dependent); ↑ death under glucose deprivation</td>
<td>Often better tolerance vs tumor metabolic stress (model-dependent)</td>
<td>P/R</td>
<td>Preferential cytotoxicity in nutrient-stressed tumor states</td>
<td>Classic finding: preferential tumor cell death under glucose deprivation via inhibition of energy metabolism (nutrient-stress selectivity).</td>
</tr>
<tr>
<td>2</td>
<td>AMPK axis</td>
<td>↑ AMPK activation (context-dependent) → ↓ anabolic drive; can couple to autophagy/translation suppression</td>
<td>↑ AMPK can be cytoprotective under ER/metabolic stress (context-dependent)</td>
<td>P/R</td>
<td>Energy-sensing shift that can suppress growth programs</td>
<td>Multiple primary sources report AMPK activation in stress contexts; note Nestronics lists “AMPKα↓” for pid 33, which may reflect a model-specific readout or a directionality error.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K / AKT / mTOR</td>
<td>↓ PI3K/AKT; ↓ mTOR signaling; ↑ autophagy-associated death (model-dependent)</td>
<td>↓ inflammatory PI3K/AKT/IKK signaling in immune/inflammatory settings</td>
<td>R/G</td>
<td>Growth-pathway suppression; autophagy-linked cytotoxicity in some models</td>
<td>Reported in ER+ breast cancer (mTOR inhibition with autophagic cell death) and inflammatory disease models (PI3K/AKT/IKKβ/NF-κB suppression).</td>
</tr>
<tr>
<td>4</td>
<td>STAT3</td>
<td>↓ STAT3 signaling → ↓ proliferation/survival; ↑ apoptosis (model-dependent)</td>
<td>Potential ↓ pro-inflammatory STAT3 outputs (context-dependent)</td>
<td>R/G</td>
<td>Anti-proliferative transcriptional reprogramming</td>
<td>Direct STAT3 inhibitory activity is repeatedly reported in cancer models (e.g., TNBC).</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB inflammatory axis</td>
<td>↓ NF-κB-dependent survival/invasion programs (context-dependent)</td>
<td>↓ NF-κB activation → ↓ IL-1β/TNF-α/IL-6; ↑ IL-10 signatures (model-dependent)</td>
<td>R/G</td>
<td>Anti-inflammatory signaling; can indirectly reduce tumor-promoting inflammation</td>
<td>Strong preclinical anti-inflammatory evidence; cancer relevance often mediated through TME/inflammation coupling.</td>
</tr>
<tr>
<td>6</td>
<td>Cell death balance</td>
<td>↑ apoptosis and/or autophagy-associated death; Bax/Bcl-2-family shifts (model-dependent)</td>
<td>Usually less pro-death in normal cells at comparable stress (model-dependent)</td>
<td>G</td>
<td>Execution of cytotoxic phenotype</td>
<td>Frequently downstream of metabolic stress + PI3K/AKT/mTOR + STAT3 changes; direction and dominance vary by model/dose.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>Exposure-limited and conjugation-dominant PK; free-parent levels may be lower than typical in-vitro dosing</td>
<td>Same PK constraints; safety margins define usable exposure</td>
<td>—</td>
<td>PK + formulation and trial-design constraints dominate translation</td>
<td>Arctiin→arctigenin gut conversion plus rapid glucuronidation/sulfation are key constraints; Phase I (GBS-01) provides human PK/safety signal but efficacy remains unproven.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>